<DOC>
	<DOCNO>NCT01101113</DOCNO>
	<brief_summary>This study design order investigate effect cinacalcet combination routine conventional medical management treatment secondary hyperparathyroidism ( SHPT ) Ca , P control . This study compare efficacy cinacalcet-based regimen unrestricted conventional care ( vitamin D phosphate binder ) achieve stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative ( KDOQI ) target dialysis patient .</brief_summary>
	<brief_title>Cinacalcet stUdy Peritoneal Dialysis Patients In Double Arm Lowing Effect OF iPTH Level</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Peritoneal dialysis patient secondary HPT ( iPTH &gt; 300 pg/mL ) &gt; 18 yr age , &lt; 70 receive PD &gt; 3 mo , intact PTH level &gt; 300 pg/ml &lt; 1000 pg/ml albumin correct Ca level &gt; = 9.0 mg/dL pregnant breastfeeding , undergone parathyroidectomy within previous 3 mo , involve clinical trial within 30 receive cinacalcet therapy previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>peritoneal dialysis</keyword>
</DOC>